-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic kidney disease (CKD) is a well-known public health problem, affecting approximately 34 million adults in the United States, accounting for more than 14% of the US population
.
Studies have reported that magnesium ions are involved in the regulation of blood pressure (BP)
Recently, the heart blood vessels authoritative magazine published a research article on Hypertension, the researchers analyzed data from 3866 participants from chronic renal insufficiency queue (CRIC Research) of
.
Linear regression assessed the association between serum magnesium and baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Heart blood vessels
The subjects' average serum magnesium level was 2.
0mEq/L (±0.
3mEq/L)
.
Higher magnesium levels are associated with lower SBP (-3.
In the time-to-event analysis, a higher baseline serum magnesium was associated with a lower risk of hypertensive events defined by the CRIC (adjusted hazard ratio of 0.
77 [95% CI 0.
46-1.
31/1mEq/L])
.
Higher magnesium levels are associated with a significantly lower risk of CKD progression (adjusted hazard ratio is 0.
It can be seen that in CKD patients, higher serum magnesium is associated with lower SBP and DBP, and lower risk of hypertension and CKD progression
.
In CKD patients, whether magnesium supplementation can optimize blood pressure control and prevent disease progression deserves further research
In CKD patients, higher serum magnesium is associated with lower SBP and DBP and lower risk of hypertension and CKD progression
Original source:
Simon Correa.